- Home
- RIME vs VCNX Comparison
RIME vs VCNX Comparison
Compare RIME & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- VCNX
- Stock Information
- Founded
- RIME 1982
- VCNX 2001
- Country
- RIME United States
- VCNX United States
- Employees
- RIME N/A
- VCNX N/A
- Industry
- RIME
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- RIME
- VCNX Health Care
- Exchange
- RIME NYSE
- VCNX Nasdaq
- Market Cap
- RIME 4.9M
- VCNX 4.5M
- IPO Year
- RIME 1994
- VCNX N/A
- Fundamental
- Price
- RIME $0.41
- VCNX $2.52
- Analyst Decision
- RIME
- VCNX
- Analyst Count
- RIME 0
- VCNX 0
- Target Price
- RIME N/A
- VCNX N/A
- AVG Volume (30 Days)
- RIME 10.6M
- VCNX 107.8K
- Earning Date
- RIME 11-19-2024
- VCNX 11-11-2024
- Dividend Yield
- RIME N/A
- VCNX N/A
- EPS Growth
- RIME N/A
- VCNX N/A
- EPS
- RIME N/A
- VCNX N/A
- Revenue
- RIME $37,788,657.00
- VCNX $356,000.00
- Revenue This Year
- RIME N/A
- VCNX N/A
- Revenue Next Year
- RIME N/A
- VCNX N/A
- P/E Ratio
- RIME N/A
- VCNX N/A
- Revenue Growth
- RIME 24.99
- VCNX N/A
- 52 Week Low
- RIME $0.35
- VCNX $1.39
- 52 Week High
- RIME $1.97
- VCNX $15.96
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- VCNX 36.74
- Support Level
- RIME N/A
- VCNX $2.03
- Resistance Level
- RIME N/A
- VCNX $3.39
- Average True Range (ATR)
- RIME 0.00
- VCNX 0.53
- MACD
- RIME 0.00
- VCNX 0.06
- Stochastic Oscillator
- RIME 0.00
- VCNX 40.50
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.